Press Releases

November 17, 2016

Vtesse Announces Dosing of First Patient in Germany for Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease

Clinicians Continue to Enroll Children with NPC at Trial Sites in France, Spain,
Turkey, the United States and the United Kingdom -- Expansion to Australia Expected Soon

Learn More
November 17, 2016

Imara Announces First Subject Dosed in Phase 1 Study of Lead Product Candidate, IMR-687

Clinical trial to evaluate the safety and tolerability of a potentially disease-modifying medicine for the treatment of sickle cell disease

Learn More
November 17, 2016

Cydan Announces the Promotion of James McArthur, Ph.D. to President, Research and Development

In this role, he will lead research and development activities across all Cydan companies

Learn More
November 17, 2016

Medicines and Healthcare Products Regulatory Agency (“MHRA”) Designates VTS-270 as a Promising Innovative Medicine

Designation is first step to inclusion in Early Access to Medicines Scheme ("EAMS"), providing patients with faster access to innovative medicines

Learn More
April 14, 2016

Cydan Development Announces Formation of Imara Inc. with $31M Series A Funding to Develop Therapeutic for Sickle Cell Disease

Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc.

Learn More